Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $721000.0.

  • Editas Medicine's Depreciation & Amortization (CF) fell 5490.93% to $721000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 129.85%. This contributed to the annual value of $5.8 million for FY2024, which is 477.05% down from last year.
  • As of Q3 2025, Editas Medicine's Depreciation & Amortization (CF) stood at $721000.0, which was down 5490.93% from $1.8 million recorded in Q2 2025.
  • Editas Medicine's Depreciation & Amortization (CF)'s 5-year high stood at $1.9 million during Q1 2025, with a 5-year trough of $721000.0 in Q3 2025.
  • For the 5-year period, Editas Medicine's Depreciation & Amortization (CF) averaged around $1.5 million, with its median value being $1.5 million (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 4573.93% in 2021, then tumbled by 5490.93% in 2025.
  • Editas Medicine's Depreciation & Amortization (CF) (Quarter) stood at $1.6 million in 2021, then rose by 1.22% to $1.6 million in 2022, then decreased by 4.76% to $1.5 million in 2023, then dropped by 8.06% to $1.4 million in 2024, then crashed by 47.79% to $721000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $721000.0 for Q3 2025, versus $1.8 million for Q2 2025 and $1.9 million for Q1 2025.